Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E.
Other stock markets
 02:10:43 2024-05-01 EDT 		5-day change 1st Jan Change
0.42 AUD -2.33% Intraday chart for Immutep Limited +9.09% +21.74%
04-30 Canaccord Starts Immutep at Buy, Price Target is AU$1.00 MT
04-24 Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer
Immutep Doses First Patient in Cancer Trial
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment
Immutep Expands Sites for Phase 1 Cancer Trial
Immutep Limited Announces Completion of Patient Enrollment in the Tacti-003 (Keynote-Pnc-34) Phase Iib Trial
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Immutep Completes Enrollment for Phase 2b Cancer Trial
Immutep Limited Announces Completion of the Safety Lead-In and Opening of the Randomized Phase Ii of the Aipac-003 Phase II/III Trial in Metastatic Breast Cancer
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer
Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. News Immutep Limited
  5. Other languages